Regulation: The FDA is overcautious on consumer genomics.
about
Personal Genome Sequencing in Ostensibly Healthy Individuals and the PeopleSeq ConsortiumNeurogenethics: An emerging discipline at the intersection of ethics, neuroscience, and genomicsThe powers of participatory medicineAnticipation of Personal Genomics Data Enhances Interest and Learning Environment in Genomics and Molecular Biology Undergraduate CoursesReclassification of genetic-based risk predictions as GWAS data accumulate.Diet and exercise changes following direct-to-consumer personal genomic testing.Genetic counseling in direct-to-consumer exome sequencing: a case report.The audacity of interpretation: Protecting patients or piling on?'Someday it will be the norm': physician perspectives on the utility of genome sequencing for patient care in the MedSeq ProjectReturn of individual genetic results in a high-risk sample: enthusiasm and positive behavioral change.A new approach to assessing affect and the emotional implications of personal genomic testing for common disease riskThe impact of direct-to-consumer personal genomic testing on perceived risk of breast, prostate, colorectal, and lung cancer: findings from the PGen studyDo physicians think genomic medicine will be useful for patient care?Explaining, not just predicting, drives interest in personal genomics.FDA's Proposed Guidance for Laboratory Developed Tests: How Should Regulators Balance the Risks and Promise of Innovation in Clinical Genetics?Marketing of personalized cancer care on the web: an analysis of Internet websitesTranslational genomics.How Well Do Customers of Direct-to-Consumer Personal Genomic Testing Services Comprehend Genetic Test Results? Findings from the Impact of Personal Genomics StudyThe social value of candidate HIV cures: actualism versus possibilism.Genetic testing in cardiovascular diseases.Reflections on the US FDA's Warning on Direct-to-Consumer Genetic Testing.Genetic screening for gynecological cancer: where are we heading?Personal Genomic Testing for Cancer Risk: Results From the Impact of Personal Genomics Study.Sequencing your genome: your future is here, but are you sure you want to know it?Implications of Personal Genomic Testing for Health Behaviors: The Case of Smoking.Personalized genetic testing and norovirus susceptibilityWhat do the changes in the aging genome mean for pharmacogenomics?Ethical issues in neurogenetics.The hidden harm behind the return of results from personal genome services: a need for rigorous and responsible evaluation.Australians' views on personal genomic testing: focus group findings from the Genioz studyA market in the making: the past, present and future of direct-to-consumer genomics
P2860
Q26749580-515B1149-7132-4091-A4A0-0BC19CCF6898Q26764827-EC40348E-AA8C-4698-8F51-7E35F8FB0A72Q28660031-5E820B68-551B-4F98-85E3-36D37C046135Q30985098-6002C11C-F230-49FE-B27A-8B05A71449D6Q31046674-F11D5570-B3EB-4901-94FC-670F82F5481BQ33623616-AFE508A9-7326-4A34-B15E-4A2D882E058CQ34144804-85DE0AA2-8B69-4BE0-B274-77742E42F2CBQ34990419-71062F82-A725-4AD4-8E96-5088CCFD642BQ35012563-2FDFE7FB-6907-4B4E-9721-BE31731B069EQ35132632-3D52FBCB-B835-49BB-81F8-6C48689FC460Q35143295-D58CD20A-2A49-42AB-B565-B66405E95117Q35807814-E41D97FC-7F87-4A16-BCFB-447E775DAD49Q35827874-A25200CD-289C-44C8-8289-AEC7DE9AC75FQ35945361-97684FC3-FA15-4E0A-AD17-BE672142C128Q36121843-4F15303D-1DBE-4978-BE63-25A88588B60FQ36770241-4AACF90C-ED4C-476D-AA21-2E30DC678355Q36950760-DDD1A5C0-0B1A-4034-A086-EA06899B23D5Q37050375-C6E2C512-5A25-4BA7-AAD5-FA6B649040B3Q37627208-282DA0EB-A2BA-4A93-92C9-22B647454086Q38203394-EC00F107-6D25-42A6-A453-3710B7A54241Q38364174-01B69D8D-A365-409D-AA66-B604B374C85EQ38659935-DD0B6416-A70F-439C-B029-3A8055C2F783Q39114110-CBEC490C-4713-4E72-BF70-C3CA1E8F28D4Q39160024-64C0C54B-80F3-462B-8E6A-0EF8D6FF0870Q39404554-802BAEF4-D293-4983-AE37-9F541F0EFE14Q41715283-085F8FB0-7842-4ED3-B2F4-C626ECF36542Q45006961-A9ABF846-4C11-4C75-87DE-27F1D6812868Q47560820-11A5B833-1B15-4E5D-B85C-934C560299ACQ47787158-D539023D-C63F-4D1A-97A2-93FCD86C2526Q56889685-6BD91B9B-5D4D-4942-B875-4FE5AEEAC7B0Q57780718-58991272-88A9-4041-999F-735D46B7238D
P2860
Regulation: The FDA is overcautious on consumer genomics.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Regulation: The FDA is overcautious on consumer genomics.
@en
Regulation: The FDA is overcautious on consumer genomics.
@nl
type
label
Regulation: The FDA is overcautious on consumer genomics.
@en
Regulation: The FDA is overcautious on consumer genomics.
@nl
prefLabel
Regulation: The FDA is overcautious on consumer genomics.
@en
Regulation: The FDA is overcautious on consumer genomics.
@nl
P356
P1433
P1476
Regulation: The FDA is overcautious on consumer genomics.
@en
P2093
Nita A Farahany
P2888
P304
P356
10.1038/505286A
P407
P577
2014-01-01T00:00:00Z
P6179
1005577280